Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population

HPV remains the most common sexually transmitted disease worldwide, despite improvements in awareness, screening, prophylactic vaccination uptake, and surgical treatment. VGX-3100 is an immunotherapy that uses electroporation to introduce DNA encoding for modified HPV-16 and HPV-18, E6-and E7 protei...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hum Vaccin Immunother
Main Authors: Hollenberg, Rebecca K., Krieger, Diane R., Samuels, Robert, Kraynyak, Kim, Sylvester, Albert, Morrow, Matthew, Boyer, Jean, Dallas, Michael, Bhuyan, Prakash K.
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2019
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7482708/
https://ncbi.nlm.nih.gov/pubmed/31860383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1695459
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares